Moreover, targeting PI3K/AKT/mTOR signaling pathway with a combination therapy of PI3K inhibitors and trastuzumab to treat HER2-positive breast cancer can ameliorate resistance and restore apoptotic effects [205]. Here, MTOR is linked to breast carcinoma.